TY - JOUR
T1 - Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias
AU - Sakai, Shio
AU - Nakaseko, Chiaki
AU - Takeuchi, Masahiro
AU - Ohwada, Chikako
AU - Shimizu, Naomi
AU - Tsukamoto, Shokichi
AU - Kawaguchi, Takeharu
AU - Jiang, Meizi
AU - Sato, Yasunori
AU - Ebinuma, Hiroyuki
AU - Yokote, Koutaro
AU - Iwama, Atsushi
AU - Fukamachi, Isamu
AU - Schneider, Wolfgang Johann
AU - Saito, Yasushi
AU - Bujo, Hideaki
N1 - Funding Information:
This study was supported in part by grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology , the Austrian Science Foundation (FWF) , the Japanese Ministry Health and Labour , Takeda Science Foundation , and Smoking Research Foundation .
PY - 2012/10/9
Y1 - 2012/10/9
N2 - Background: LR11/SorLA, a receptor interacting with CD87 on monocytes and macrophages, is highly expressed on human immature hematopoietic stem cells. However, it is unknown whether LR11 is expressed on premature leukemic cells, and whether the levels of circulating soluble LR11 (sLR11) shed from leukemic cells correlate with disease state. Methods: The expression of LR11 on leucocytes and leukemic cells was examined by flow cytometry. Serum sLR11 levels were measured by ELISA in patients with various hematological diseases, including 43 acute myeloid leukemia (AML) and 23 acute lymphoblastic leukemia (ALL) patients. Data were subjected to statistical analysis for validation of sLR11 levels and patients' clinical data. Results: LR11 is specifically expressed in monocytes, and surface levels on leukemic cells are highly induced in both AML and ALL. sLR11 levels of acute leukemia patients were significantly increased (P < 0.001) (ALL, 73.5 ± 93.5. ng/ml; AML, 26.8 ± 29.1. ng/ml) in comparison to controls (9.2 ± 3.3. ng/ml). Patients with AML and ALL in remission showed significantly decreased sLR11 levels to below 20. ng/ml. Conclusions: LR11 and its released soluble form are strongly elevated in acute leukemias. Remarkably, this increase in circulating sLR11 levels is ameliorated at complete remission.
AB - Background: LR11/SorLA, a receptor interacting with CD87 on monocytes and macrophages, is highly expressed on human immature hematopoietic stem cells. However, it is unknown whether LR11 is expressed on premature leukemic cells, and whether the levels of circulating soluble LR11 (sLR11) shed from leukemic cells correlate with disease state. Methods: The expression of LR11 on leucocytes and leukemic cells was examined by flow cytometry. Serum sLR11 levels were measured by ELISA in patients with various hematological diseases, including 43 acute myeloid leukemia (AML) and 23 acute lymphoblastic leukemia (ALL) patients. Data were subjected to statistical analysis for validation of sLR11 levels and patients' clinical data. Results: LR11 is specifically expressed in monocytes, and surface levels on leukemic cells are highly induced in both AML and ALL. sLR11 levels of acute leukemia patients were significantly increased (P < 0.001) (ALL, 73.5 ± 93.5. ng/ml; AML, 26.8 ± 29.1. ng/ml) in comparison to controls (9.2 ± 3.3. ng/ml). Patients with AML and ALL in remission showed significantly decreased sLR11 levels to below 20. ng/ml. Conclusions: LR11 and its released soluble form are strongly elevated in acute leukemias. Remarkably, this increase in circulating sLR11 levels is ameliorated at complete remission.
KW - ALL
KW - AML
KW - CD87
KW - LR11/SorLA
KW - Monocyte
KW - UPAR
UR - http://www.scopus.com/inward/record.url?scp=84864041190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864041190&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2012.06.025
DO - 10.1016/j.cca.2012.06.025
M3 - Article
C2 - 22750733
AN - SCOPUS:84864041190
SN - 0009-8981
VL - 413
SP - 1542
EP - 1548
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
IS - 19-20
ER -
